Ekso Bionics Holdings, Inc. (EKSO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EKSO Stock Summary
- EKSO has a higher market value than only 6.71% of US stocks; more precisely, its current market capitalization is $36,428,678.
- With a year-over-year growth in debt of -42.38%, Ekso Bionics Holdings Inc's debt growth rate surpasses only 9.5% of about US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for EKSO comes in at -106.27% -- higher than that of only 3.54% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Ekso Bionics Holdings Inc, a group of peers worth examining would be AWH, NVRO, STIM, TAOP, and IGC.
- EKSO's SEC filings can be seen here. And to visit Ekso Bionics Holdings Inc's official web site, go to www.eksobionics.com.
EKSO Valuation Summary
- EKSO's price/sales ratio is 6.5; this is 42.73% lower than that of the median Healthcare stock.
- Over the past 90 months, EKSO's price/sales ratio has gone down 61.8.
- EKSO's price/sales ratio has moved down 61.8 over the prior 90 months.
Below are key valuation metrics over time for EKSO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| EKSO | 2021-08-31 | 6.5 | 1.5 | -9.4 | -2.7 |
| EKSO | 2021-08-30 | 6.3 | 1.5 | -9.1 | -2.4 |
| EKSO | 2021-08-27 | 6.4 | 1.5 | -9.1 | -2.5 |
| EKSO | 2021-08-26 | 6.3 | 1.5 | -9.1 | -2.4 |
| EKSO | 2021-08-25 | 6.3 | 1.4 | -9.0 | -2.3 |
| EKSO | 2021-08-24 | 6.2 | 1.4 | -8.9 | -2.2 |
EKSO Growth Metrics
- Its 5 year revenue growth rate is now at -23.86%.
- Its 5 year net cashflow from operations growth rate is now at 41.98%.
- Its 3 year price growth rate is now at -69%.
The table below shows EKSO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 11.246 | -11.156 | -9.764 |
| 2021-09-30 | 9.424 | -9.821 | -10.877 |
| 2021-06-30 | 9.272 | -8.616 | -6.467 |
| 2021-03-31 | 9.325 | -9.033 | -16.961 |
| 2020-12-31 | 8.882 | -8.755 | -15.825 |
| 2020-09-30 | 10.349 | -8.51 | -14.57 |
EKSO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- EKSO has a Quality Grade of D, ranking ahead of 7.97% of graded US stocks.
- EKSO's asset turnover comes in at 0.242 -- ranking 100th of 104 Machinery stocks.
- MOG.A, DRQ, and CECE are the stocks whose asset turnover ratios are most correlated with EKSO.
The table below shows EKSO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.242 | 0.615 | -1.072 |
| 2021-03-31 | 0.303 | 0.608 | -2.750 |
| 2020-12-31 | 0.426 | 0.571 | -2.648 |
| 2020-09-30 | 0.489 | 0.538 | -2.401 |
| 2020-06-30 | 0.529 | 0.511 | -2.663 |
| 2020-03-31 | 0.556 | 0.493 | -1.145 |
EKSO Price Target
For more insight on analysts targets of EKSO, see our EKSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
EKSO Stock Price Chart Interactive Chart >
EKSO Price/Volume Stats
| Current price | $1.81 | 52-week high | $6.10 |
| Prev. close | $1.78 | 52-week low | $1.54 |
| Day low | $1.77 | Volume | 34,600 |
| Day high | $1.85 | Avg. volume | 50,399 |
| 50-day MA | $2.41 | Dividend yield | N/A |
| 200-day MA | $3.21 | Market Cap | 23.25M |
Ekso Bionics Holdings, Inc. (EKSO) Company Bio
Founded in 2005 in Richmond, California, Ekso Bionics Holdings Inc employs approximately 92 people that design, develop, and sell wearable bionic human exoskeletons that have applications in healthcare, industrial, military, and consumer markets. The company’s first product, HULC was developed for the military in partnership with Lockheed Martin, enhancing soldier capabilities to allow them to carry heavier loads over further distances. The EksoNR is currently the only FDA-cleared exoskeleton for treatment of ABI, helping physical therapists, physiatrists, and doctors to clinically rehabilitate patients. The company’s CEO is Jack Peurach, who served as Executive Vice President, Products for SunPower Corp before becoming Ekso’s Chief Executive Officer.
Latest EKSO News From Around the Web
Below are the latest news stories about Ekso Bionics Holdings Inc that investors may wish to consider to help them evaluate EKSO as an investment opportunity.
Ekso Bionics Holdings, Inc. (EKSO) CEO Steven Sherman on Q4 2021 Results - Earnings Call TranscriptNo summary available. |
Ekso Bionics Holdings GAAP EPS of -$0.23, revenue of $4.1MEkso Bionics Holdings press release (EKSO): Q4 GAAP EPS of -$0.23.Revenue of $4.1M (+82.2% Y/Y).Cash on hand at December 31, 2021 was $40.4 million, compared to $12.9 million at… |
Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue EstimatesEkso Bionics (EKSO) delivered earnings and revenue surprises of 8% and 1.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
Ekso Bionics Reports Fourth Quarter and Year End 2021 ResultsRICHMOND, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2021. Recent Highlights and Accomplishments Reported record revenue of $4.1 million in the fourth quarter of 2021Achieved gross margin of approximately 59% in the fourth quarter of 2021Booked a total of 30 EksoNR units in the f |
Ekso Bionics to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022RICHMOND, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2021 after the close of trading on Thursday, February 24, 2022. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to discuss the financial results and recent business developments. |
EKSO Price Returns
| 1-mo | -26.12% |
| 3-mo | -29.57% |
| 6-mo | -47.38% |
| 1-year | -68.69% |
| 3-year | -91.68% |
| 5-year | -88.83% |
| YTD | -31.70% |
| 2021 | -56.77% |
| 2020 | 4.52% |
| 2019 | -68.47% |
| 2018 | -41.78% |
| 2017 | -46.48% |
Continue Researching EKSO
Want to do more research on Ekso Bionics Holdings Inc's stock and its price? Try the links below:Ekso Bionics Holdings Inc (EKSO) Stock Price | Nasdaq
Ekso Bionics Holdings Inc (EKSO) Stock Quote, History and News - Yahoo Finance
Ekso Bionics Holdings Inc (EKSO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...